|RxNews Recap for Tuesday 12-29-09|
|By Mary Davila|
|Tuesday, 29 December 2009 19:19|
Below is a list of the companies that made news in the healthcare sector on Tuesday, December 29, 2009.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and collaborators from the David H. Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MIT) today announced the publication of new data in the journal Proceedings of the National Academy of Sciences (PNAS) describing further advancements in discovery and development of novel “lipidoid” formulations for the systemic delivery of RNAi therapeutics.
AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-science company dedicated to the development of novel diagnostics and drugs for humans and animals, reported on its progress and plans for the Premarket Notification 510(k) submission of its ELISA format AppyScore™ test. AppyScore is the first blood-based test designed to aid in the evaluation of patients suspected of having acute appendicitis.
Bionovo, Inc. (Nasdaq: BNVI) announced today the publication of results from its study on the anti-tumor mechanism of BN107.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) invites investors and the general public to listen to a webcast of an analyst meeting on Thursday, January 7, 2010, at 3:00 p.m. ET.
INTERNATIONAL ENERGY LTD., INC. (PINKSHEETS:ILGL) is proud to announce that effective immediately, International Energy is open for business and is starting to roll the assets of the corporation's previously announced business plan onto the books / balance sheet, as assets, of International Energy.
Luna Innovations Incorporated (NASDAQ: LUNA) has acquired certain intellectual property assets of Tego Biosciences, its main competitor in developing medicines based on carbon nanomaterials.
Proteonomix, Inc. (PINKSHEETS: PROT) announces that Joel Pensley has resigned as secretary, director and general counsel and Roger Fidler has joined the Company as director and general counsel; and Steven Byle, presently a director, has assumed the role of secretary.
VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation medical therapies to address unmet needs in obesity, diabetes and sexual health, announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of Qnexa, its investigational drug for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or central adiposity.
Trimeris, Inc. (Nasdaq: TRMS) (“Trimeris”) today announced that in connection with the Agreement and Plan of Merger dated October 2, 2009, as amended, brand among Trimeris, Arigene Co., Ltd. and RTM Acquisition Company (“Arigene” and “Purchaser,” respectively) (the “Merger Agreement”), Arigene has informed Trimeris through counsel that Arigene intends to terminate the tender offer for all of Trimeris’ outstanding shares of common stock because Arigene was unable to secure sufficient financing for purposes of funding the tender offer. The tender offer expired on Monday, December 28, 2009.
VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on December 29, 2009, it received a written notice from the listing qualifications staff of the NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on January 4, 2010 and that NASDAQ would initiate procedures to delist the Company's common stock.
Walgreens (NYSE, NASDAQ: WAG), the nation’s largest drugstore chain and industry leader with more than 17,000 certified or licensed immunizers, is now offering H1N1 vaccinations at all of its pharmacies throughout Massachusetts.